- dsm-firmenich completed a €175 million cost synergy from its merger.
- The company plans a €540 million share repurchase program.
- 2026 outlook: 2-4% organic sales growth, ~20% EBITDA margin, 11-12% cash conversion.
- Mid-term target for Adjusted Gross Operating Free Cash Flow increased to ≥14%.
Event Overview
dsm-firmenich held an Investor Event in London, focusing on strategic and operational progress. The event featured presentations from key executives, including CEO Dimitri de Vreeze and CFO Ralf Schmeitz.
Financial Strategy
The company has achieved €175 million in cost synergies following its merger. It plans to enhance financial performance through a multi-lever plan targeting growth, EBITDA margin expansion, and improved cash conversion.
2026 Outlook
For 2026, dsm-firmenich anticipates 2-4% organic sales growth, an adjusted EBITDA margin of around 20%, and cash conversion of 11-12%. These projections consider ongoing macroeconomic challenges and FX effects.
Mid-term Targets
The company aims to accelerate performance on key financial targets by 2027, with a mid-term target for Adjusted Gross Operating Free Cash Flow increased from ≥10% to ≥14%.
Share Repurchase Program
dsm-firmenich announced a €540 million share repurchase program, with €500 million allocated to reducing issued capital and €40 million for share-based compensation plans.
